SignalFDA/Bio

BAYER’S ASKBIO COMPLETES ENROLLMENT IN PHASE 2 HEART FAILURE GENE THERAPY TRIAL - SEEKINGALPHA

Phase 2 enrollment completion marks a key clinical milestone for heart failure gene therapy.

What changed

Phase 2 enrollment completion marks a key clinical milestone for heart failure gene therapy.

Why it matters

Phase 2 enrollment completion marks a key clinical milestone for heart failure gene therapy. — impact context not separately stored; see What changed.

Sources

seekingalpha